Skip to main content

Table 3 Correlation between immunohistochemistry scores for hormone receptors and response to endocrine therapy in breast cancer

From: Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer

Receptor Responders (n = 35)a Nonresponders (n = 40)a P b P c
ER-α (1D5) 5.8 ± 2.3 (7; 0–8) 4.1 ± 2.9 (5; 0–8) 0.0045* 0.0046*
ER-α Ser118 4.3 ± 2.6 (5; 0–8) 4.2 ± 2.4 (4; 0–8) 0.90 0.96
ER-α Ser167 2.5 ± 2.0 (2; 0–6) 1.6 ± 1.7 (2; 0–5) 0.033* 0.025*
ER-β1 4.2 ± 2.2 (4; 0–8) 4.5 ± 2.3 (5; 0–8) 0.43 0.57
ER-βcx/β2 3.1 ± 2.4 (3; 0–8) 3.0 ± 2.5 (2; 0–8) 0.72 0.80
PR (636) 5.5 ± 2.5 (6; 0–8) 3.6 ± 2.7 (4; 0–8) 0.0008* 0.0014*
PRA 4.6 ± 2.0 (5; 0–8) 2.4 ± 2.5 (2; 0–8) 0.0001* <0.0001*
PRB 4.0 ± 2.1 (4; 0–8) 2.7 ± 2.4 (3; 0–8) 0.013* 0.015*
  1. aValues are means ± standard deviations (medians; ranges). bMann–Whitney U test. cUnpaired t-test. *P <0.05. ER, estrogen receptor; PR(A,B), progresterone receptor (A,B).